Katherine Payne, MSc, Ph.D.


Version française à venir


Katherine was awarded a personal chair in health economics at The University of Manchester in August 2010. She is based within the Manchester Centre for Health Economics. Katherine registered as a pharmacist in 1990 and went on to work as a hospital pharmacist for three years gaining a diploma in clinical pharmacy. After gaining awards to study an MSc in Health Economics (York; 1994) and a PhD in health economics (Manchester; 2000), she is now an academic health economist with over 20 years of experience. She holds honorary positions with: the School of Pharmacy, University of Nottingham; PHG Foundation, Cambridge; Central Manchester University Hospitals NHS Foundation Trust; and Nowgen, Manchester. Katherine has an interest in the economics of genomic technologies and services and the application to stratified medicine. In September 2007, Katherine was awarded a five-year Research Councils UK Academic Fellowship in Health Economics to focus on the evaluation and valuation of genomic technologies including genomic-based diagnostics and pharmacogenomic tests. Katherine was a member of a NICE Technology Appraisal Committee between October 2003 and 2012. Katherine has also served as a panel member of a number of grant funding bodies in, for example, the UK, Canada, France and Luxembourg. 


Ongoing and recent projects include: evaluating an integrated model of service delivery and the use of new sequencing technologies for the diagnosis of inherited retinal dystrophies; identifying and costing pathways of care for people with inherited ataxia; building an economic model to identify the most appropriate interval for breast cancer screening; economic evaluation of stratified breast screening programmes; developing an approach to the health technology assessment of whole genome sequencing; economic evaluations of different applications of stratified medicine in rheumatoid arthritis, psoriasis and lupus; and using stated preference methods to value the balance between the risks and benefits of healthcare interventions.